CD274 and non-small cell lung carcinoma: The POSEIDON trial also suggested that in patients with advanced NSCLC, chemotherapy combined with PD‐L1 and CTLA‐4 inhibitors (triple combination: carboplatin + paclitaxel + durvalumab + tremelimumab) offers durable long‐term OS benefits compared with chemotherapy alone.238